	US 12,492,250 B2
	suPAR and prediction and treatment of acute kidney injury
Jochen Reiser, Chicago, IL (US); Salim Hayek, Ann Arbor, MI (US); and Arshed A. Quyyumi, Atlanta, GA (US)
Assigned to Emory University, Atlanta, GA (US); and Rush University Medical Center, Chicago, IL (US)
Appl. No. 17/278,959
Filed by Jochen Reiser, Chicago, IL (US); Salim Hayek, Ann Arbor, MI (US); and Arshed A. Quyyumi, Atlanta, GA (US)
PCT Filed Sep. 30, 2019, PCT No. PCT/US2019/053802 § 371(c)(1), (2) Date Mar. 23, 2021, PCT Pub. No. WO2020/069498, PCT Pub. Date Apr. 2, 2020.
Claims priority of provisional application 62/738,403, filed on Sep. 28, 2018.
Prior Publication US 2022/0135669 A1, May 5, 2022
Int. Cl. C07K 16/28 (2006.01); A61P 13/12 (2006.01); C07K 14/705 (2006.01); G01N 33/68 (2006.01)

CPC C07K 16/28 (2013.01) [A61P 13/12 (2018.01); C07K 14/705 (2013.01); G01N 33/6803 (2013.01); C07K 2317/24 (2013.01)]

9 Claims

1. A method of treating or reducing the incidence or severity of acute kidney injury induced by a contrast agent in a human patient, the method comprising:

measuring or having measured a level of soluble urokinase plasminogen activator receptor (suPAR) in a biological sample from the human patient exposed to a contrast agent;

determining or having determined the level of suPAR in the sample is a suPAR level of about 3 ng/ml or greater; and

administering a therapeutically effective amount of an anti-suPAR antibody or antigen-binding fragment thereof that specifically binds to suPAR to the human patient thereby reducing the incidence or severity of acute kidney injury induced by the contrast agent.